

Invitation

Stockholm, 27 September 2019

Invitation to press conference today Friday September 27, 2019

A conference call for investors, analysts and media will be held at 1.00 pm CET today, where CEO Christian Kinch and CFO Cecilia Edström will present the license agreement with Zimmer Biomet and answer questions. The presentation for the conference call will be available at Bactiguard's website www.bactiguard.se/en/for-investors/presentations

To participate in the conference call, please dial +46 8 566 426 95

For further information, please contact:

Cecilia Edström, CFO and deputy CEO, cell phone: +46 72 226 23 28

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard's coating are market leading in the USA and Japan. Bactiguard's own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives at www.bactiguard.com